O
Organon & Co. (OGN)
NYQ – Real vaqt narxi. Valyuta: USD
13.31
-0.02 (-0.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
13.21
-0.09 (-0.70%)
Bozor oldidan: May 13, 2026, 4:07 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
13.31
-0.02 (-0.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
13.21
-0.09 (-0.70%)
Bozor oldidan: May 13, 2026, 4:07 AM EDT
Organon & Co. Qo'shma Shtatlar, Yevropa, Kanada, Yaponiya, Osiyo-Tinch okeani mintaqasining qolgan qismi, Xitoy, Lotin Amerikasi, Yaqin Sharq, Rossiya, Afrika va xalqaro miqyosda retseptura terapiyalari va tibbiy qurilmalar orqali ayollar salomatligi bo'yicha yechimlarni ishlab chiqadi va yetkazib beradi. Kompaniyaning ayollar salomatligi portfelida kontratseptiv va tug'ilishga qarshi vositalar markalari mavjud, masalan, Nexplanon, uzoq muddatli qaytariladigan kontratseptiv; NuvaRing, oylik vaginal kontratseptiv halqa; Cerazette, Marvelon va Mercilon homiladorlikni oldini olish uchun; Follistim AQ, tuxumdon follikulalarining rivojlanishini rag'batlantirish uchun ishlatiladi; Elonva, follikulani stimulyator; Ganirelix acetate in'ektsiyasi, in'ektsion antagonist; Jada postpartum bachadon qon ketishi va gemorragiyasi uchun; va Xaciato bakterial vaginosis uchun. Uning biosimilar portfelida immünologik mahsulotlar, masalan, Brenzys, Renflexis va Hadlima; onkologik mahsulotlar, shu jumladan Ontruzant va Aybintio; Bildyos va Bilprevda, rekombinant anti-RANKL inson monoklonal antitelalari; va Poherdy, neu retseptor antagonisti mavjud. Kompaniya shuningdek, Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet va Zocor markalari ostida xolesterinni o'zgartiruvchi dorilarni; Cozaar va Hyzaar gipertenziya uchun; Singulair, Dulera, Zenhale va Asmanex markalari ostida astma alomatlarini nazorat qilish va oldini olish uchun respirator mahsulotlarni, shuningdek Nasonex, Clarinex va Aerius markalari ostida mavsumiy allergik rinitni taklif etadi. Qo'shimcha ravishda, u Vtama, Diprosone va Elocon markalari ostida dermatologik mahsulotlarni; Fosamax markasi ostida suyak salomatligi mahsulotlarini; va Arcoxia, Diprospan va Celestone markalari ostida opioid bo'lmagan og'riqni boshqarish mahsulotlarini, shuningdek Proscar simptomatik yaxshi sifatli prostata giperplaziyasi uchun; va Propecia erkaklar tipidagi soch to'kilishi uchun taqdim etadi. Kompaniya dori vositalari ulgurji va chakana savdogarlariga, shifoxonalar, klinikalarga, davlat muassasalariga, sog'liqni saqlash tashkilotlariga, dorixonalar imtiyozlari menejerlariga va boshqa muassasalarga xizmat ko'rsatadi. Organon & Co. 1923 yilda tashkil etilgan va shtab-kvartirasi Nyu-Jersi shtatining Jersi-Siti shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive VP, Head of Research & Development and Chief Medical Officer |
| Mr. Aaron Falcione | Executive VP & Chief Human Resources Officer |
| Mr. Daniel Karp | Chief Strategy Officer & Head of Corporate Development |
| Mr. Joseph T. Morrissey Jr. | Chief Executive Officer |
| Mr. Kirke Weaver | Executive VP, General Counsel & Corporate Secretary |
| Mr. Matthew M. Walsh C.F.A. | Executive VP & CFO |
| Mr. Vittorio Nisita | Executive VP and Head of Enterprise Services & Solutions |
| Ms. Carrie Smith Cox | Executive Chair of the Board |
| Ms. Jennifer Halchak | Head of Investor Relations |
| Ms. Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | 10-Q | ogn-20260331.htm |
| 2026-04-30 | 8-K | tm2613165d1_8k.htm |
| 2026-04-27 | DEFA14A | d29178ddefa14a.htm |
| 2026-04-27 | 8-K | d38652d8k.htm |
| 2026-04-24 | DEFA14A | defa_14a_fy2025.htm |
| 2026-04-24 | DEF 14A | ogn-ogn_proxy_2026_html_only.pdf |
| 2026-02-24 | 10-K | ogn-20251231.htm |
| 2026-02-20 | 8-K | tm266880d1_8k.htm |
| 2026-02-12 | 8-K | tm266144d1_8k.htm |
| 2025-11-10 | 10-K/A | ogn-20241231x10ka.htm |